Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Update on ConfIdeS phase III trial of imlifidase in highly sensitized kidney transplant patients – Hansa Biopharma

Written by | 17 Oct 2023

Hansa Biopharma announced randomization for the US ConfIdeS trial is expected to conclude in mid-2024. The ConfIdeS trial is an open-label, controlled, randomized Phase III trial evaluating 12-month… read more.

Immunosuppressive drug’s blood level variability may identify pediatric kidney transplant recipients at risk of rejection

Written by | 2 Aug 2022

Although kidney transplantation is the most effective treatment for children with kidney failure, rejection of the transplanted organ by the recipient’s immune system is a major concern. Transplant… read more.

Positive early access decision by French Haute Autorité de Santé to use Idefirix as desensitization treatment for highly sensitized kidney transplant patients – Hansa Biopharma AB

Written by | 21 Mar 2022

Hansa Biopharma AB, the pioneer in enzyme technology for rare immunological conditions, announced that its first-in-class treatment Idefirix (imlifidase) has been granted early access post marketing authorization (Autorisation… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.